Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-epitope mRNA vaccine (HIV-1)
- Development stage
- Preclinical
- Lead developer
- National Institutes of Biomedical Innovation, Health and Nutrition
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Multi-epitope mRNA vaccine (HIV-1) refers to a class of investigational mRNA-based vaccines designed to target multiple conserved epitopes of the human immunodeficiency virus type 1 (HIV-1). These vaccines typically encode a tandem array of cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and/or B-cell epitopes derived from key HIV-1 proteins such as gp120, Gag, or Nef. By utilizing optimized flanking sequences to enhance antigen processing and MHC class I presentation, these vaccines aim to elicit robust, multifunctional CD8+ T-cell and humoral immune responses. Development of these candidates is being explored by various academic and research institutions, including the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) and the University of Bordeaux, as a potential therapeutic or preventive strategy to achieve a functional cure for HIV-1.
- Other names
- multi-epitope HIV-1 mRNA vaccinemulti-epitope mRNA HIV-1 vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CXCR4 (C-X-C motif chemokine receptor 4)CD4 (T lymphocyte surface antigen)RLR (RIG-I-like receptors)MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on multi-epitope mRNA vaccine (HIV-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-epitope mRNA vaccine (HIV-1).